MX2021012548A - Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. - Google Patents

Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.

Info

Publication number
MX2021012548A
MX2021012548A MX2021012548A MX2021012548A MX2021012548A MX 2021012548 A MX2021012548 A MX 2021012548A MX 2021012548 A MX2021012548 A MX 2021012548A MX 2021012548 A MX2021012548 A MX 2021012548A MX 2021012548 A MX2021012548 A MX 2021012548A
Authority
MX
Mexico
Prior art keywords
methods
skin diseases
topical compositions
inflammatory skin
treating inflammatory
Prior art date
Application number
MX2021012548A
Other languages
English (en)
Inventor
Matthew Davidson
Julie Saiki
Johan Andreasson
Original Assignee
Azora Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azora Therapeutics Inc filed Critical Azora Therapeutics Inc
Publication of MX2021012548A publication Critical patent/MX2021012548A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones y métodos para tratar afecciones, dolencias o enfermedades de la piel, tales como enfermedades cutáneas autoinflamatorias como psoriasis, dermatitis, pioderma gangrenoso, pustulosis palmoplantar, prurigo nodular y/o hidradenitis supurativa. Las composiciones comprenden un agente que modula el receptor de hidrocarburos de arilos, en particular un agente que agoniza el receptor. En una modalidad, el agente es el índigo o un derivado del índigo, tal como la indirrubina.
MX2021012548A 2019-04-17 2020-04-16 Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel. MX2021012548A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835451P 2019-04-17 2019-04-17
US201962924611P 2019-10-22 2019-10-22
PCT/US2020/028581 WO2020214855A1 (en) 2019-04-17 2020-04-16 Topical compositions and methods for treating inflammatory skin diseases

Publications (1)

Publication Number Publication Date
MX2021012548A true MX2021012548A (es) 2023-01-05

Family

ID=70614619

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012548A MX2021012548A (es) 2019-04-17 2020-04-16 Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
MX2023000291A MX2023000291A (es) 2019-04-17 2021-10-13 Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000291A MX2023000291A (es) 2019-04-17 2021-10-13 Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.

Country Status (10)

Country Link
US (3) US11154533B2 (es)
EP (2) EP3955889A1 (es)
JP (2) JP7085073B2 (es)
KR (2) KR20230110821A (es)
CN (1) CN114206312A (es)
AU (2) AU2020258452B2 (es)
CA (1) CA3132958A1 (es)
MX (2) MX2021012548A (es)
TW (1) TW202106295A (es)
WO (1) WO2020214855A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
NO2699580T3 (es) 2014-01-24 2018-02-24
US12059424B2 (en) 2018-03-01 2024-08-13 Astrazeneca Ab Pharmaceutical compositions comprising (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
EP3955889A1 (en) 2019-04-17 2022-02-23 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
CN116194073A (zh) 2020-07-21 2023-05-30 化美有限责任公司 二酯化妆品制剂及其用途
EP4330222A1 (en) * 2021-07-02 2024-03-06 Annji Pharmaceutical Co., Ltd. Topical formulation of dimethylcurcumin
EP4380918A1 (en) * 2021-08-06 2024-06-12 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Prodrugs of tapinarof
CN113462770B (zh) * 2021-08-25 2023-03-31 中国医科大学附属第一医院 趋化因子作为玫瑰痤疮诊断的分子标志物
CN118695864A (zh) * 2022-02-16 2024-09-24 英斯梅德股份有限公司 用于治疗化脓性汗腺炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases
WO2024076731A1 (en) * 2022-10-06 2024-04-11 Regranion, Llc Methods and compositions for treating hidradenitis suppurativa
CN118265525A (zh) * 2022-10-10 2024-06-28 上海泽德曼医药科技有限公司 二苯乙烯衍生物用于预防和/或治疗溃疡的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981586A (en) * 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
WO2010050889A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
US10967031B2 (en) 2010-12-28 2021-04-06 Kamedis Ltd. Synergistic herbal compositions with prebiotic properties for treatment of skin infections, allergies and inflammation
TWI438000B (zh) * 2011-02-18 2014-05-21 Galderma Res & Dev 青黛之經油萃取的產物及其製備方法與用途
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
CN104435505A (zh) * 2015-01-09 2015-03-25 于成伟 一种治疗直肠炎的灌肠剂及其制备方法
BR112017021190B1 (pt) 2015-04-09 2021-12-21 Galderma Sa. Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis
TW201642890A (zh) 2015-04-09 2016-12-16 高德美公司 以青黛或產靛藍植物提取物治療異位性皮膚炎
US11122997B2 (en) 2015-04-17 2021-09-21 Mayo Foundation For Medical Education And Research Modulating the aryl hydrocarbon receptor system to treat major depressive disorder
EP3093016A1 (en) * 2015-05-14 2016-11-16 DIEFFETTI Cosmetici S.r.l. semplificata Compositions for the treatment of psoriasis
JO3680B1 (ar) * 2015-05-21 2020-08-27 Dermavant Sciences GmbH تركيبات صيدلانية موضعية
EP3955889A1 (en) 2019-04-17 2022-02-23 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases

Also Published As

Publication number Publication date
US20240293366A1 (en) 2024-09-05
EP3955889A1 (en) 2022-02-23
WO2020214855A1 (en) 2020-10-22
JP7085073B2 (ja) 2022-06-15
AU2022246403A1 (en) 2022-11-03
AU2020258452A1 (en) 2021-11-04
US20210186931A1 (en) 2021-06-24
US20220023259A1 (en) 2022-01-27
KR20230110821A (ko) 2023-07-25
EP4252844A3 (en) 2023-12-06
KR20220022115A (ko) 2022-02-24
TW202106295A (zh) 2021-02-16
JP2022116295A (ja) 2022-08-09
AU2020258452B2 (en) 2022-10-20
CA3132958A1 (en) 2020-10-22
MX2023000291A (es) 2023-02-09
EP4252844A2 (en) 2023-10-04
US11154533B2 (en) 2021-10-26
JP2022522540A (ja) 2022-04-19
CN114206312A (zh) 2022-03-18

Similar Documents

Publication Publication Date Title
MX2023000291A (es) Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
CO2021016768A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CO2021016765A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2015016277A (es) Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa.
BR112018012255A2 (pt) método para tratar câncer
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
CR20220325A (es) Fluoroalquil-oxadiazoles y sus usos
FI20115135L (fi) Mikrofibrilloitu selluloosa käytettäväksi erityisesti atooppisen ihotulehduksen ja psoriasiksen hoidossa
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CL2019001014A1 (es) Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CL2022001006A1 (es) Inhibidores de tim-3 y sus usos
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.